This article is more than 5 years old. Information may no longer be current.
Once-daily dose of raltegravir suppressed HIV viremia
Click Here to Manage Email Alerts
BRUSSELS — A once-daily dose of 800 mg raltegravir maintained virological suppression among patients receiving HIV treatment, researchers reported here.
“There is uncertainty about efficacy of raltegravir given at the dose of 800 mg once daily compared to the FDA-approved dose of 400 mg twice daily in patients with suppressed viremia,” Fabienne Caby, MD, of Hôpital Pitié-Salpêtrière in Paris, said during her presentation.
Caby and colleagues conducted an observational study that included 71 patients who were followed for 48 weeks. They were treated with a once-daily dose of 800 mg raltegravir (Isentress, Merck) after having being virologically suppressed for at least 6 months. Patients had been treated for a median of 14 years and had received a median of five lines of ART. Seventeen patients had received 400 mg twice-daily raltegravir for a median of 8 months before starting the single-dose treatment.
Three patients experienced virological failure: one at week 24 and two at week 28. Two cases were associated with raltegravir resistance. All of the patients had received the treatment with two nucleoside reverse transcriptase inhibitors (NRTI) and had previously failed on NRTI regimens responsible for drug resistance mutations.
“We believe in the efficacy of raltegravir 800 mg once daily in pre-treated patients with suppressed viremia as long as it is associated with a fully active backbone regimen,” Caby said. “It requires access to the entire ART history and all previous HIV genotyping test results.”
For more information:
Caby F. #BPD1/7. Presented at: 14th European AIDS Conference; Oct. 16-19, 2013; Brussels.